You are here

Noncontact Remote Monitoring for the Detection of Opioid-Induced Respiratory Depression

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DA058470-01
Agency Tracking Number: R43DA058470
Amount: $325,001.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: DA23-021
Timeline
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-06-15
Award End Date (Contract End Date): 2024-05-31
Small Business Information
132 Washington St., Suite 305
Hoboken, NJ 07030
United States
DUNS: 078572678
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 BEHNOOD GHOLAMI
 (347) 774-1617
 bgholami@autonomoushealthcare.com
Business Contact
 BEHNOOD GHOLAMI
Phone: (347) 774-1617
Email: bgholami@autonomoushealthcare.com
Research Institution
N/A
Abstract

The US opioid crisis continues to have a catastrophic impact on human lives and the ongoing COVID-19
pandemic is compounding its effects. Based on the statistics published by the CDC, 91,799 drug overdose
deaths occurred in the US in 2020, where the age-adjusted overdose deaths increased by 31% from 2019 to
2020. In addition, opioids, which cause respiratory depression, were involved in 75% of all drug overdose
deaths in the US. We propose to build on our work in non-invasive monitoring of vital signs to develop an FDA-
regulated medical device with a primary application in monitoring patients for opioid-induced respiratory
depression. This includes at-home monitoring of patients with chronic pain being treated with high-dose opioid
prescription medications or patients suffering from opioid use disorder (OUD) as well as monitoring subjects
with OUD at supervised injection sites (also known as supervised consumption spaces). Our overall goal is to
develop a non-contact multi-modal monitoring system for the detection of opioid-induced respiratory
depression at home and in supervised injection sites. While radar is capable of penetrating through clothing
and blankets to measure chest wall movements resulting from respiration, it requires the guidance of depth
imaging to target a person and the chest area. Our specific aims are: 1. Estimate tidal volume using a
noncontact monitoring system. Our current technology is capable of detecting respiratory rate with a high
degree of accuracy for stationary subjects. However, robust detection of respiratory depression involves
monitoring of respiratory rate, pattern, and depth (i.e., tidal volume). As part of this specific aim, we will develop
a framework to estimate tidal volume of a stationary subject using radar and depth information, where we
estimate tidal volume from chest wall displacements. Furthermore, we will extract features to characterize
respiratory pattern from the acquired radar signal. As a primary validation of this estimation framework, our
system will be tested on 20 healthy volunteers. The outcome of the test will provide us with preliminary data
regarding the accuracy of the radar and the depth-based tidal volume estimation as compared with the gold
standard. 2. Develop and validate a framework for integrating data from sensors to detect respiratory
depression. In this specific aim, we will develop a framework to use the respiratory rate, respiratory pattern,
and tidal volume information from the radar and depth camera to determine if respiratory depression has
occurred. This involves a two-step approach, where we extract respiratory features to characterize respiratory
patterns to complement respiratory rate and tidal volume, and then use a machine learning model to detect the
occurrence of respiratory depression. To help with design the right model, we will collect data using our radar
and depth imaging system from anesthetized pigs going through opioid-induced respiratory depression.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government